Crossover Search

Crossover Search Crossover Search is a boutique Life Sciences Search Firm. Crossover Search is a boutique search firm dedicated to the life sciences industry.

Since 2008, we have partnered with a broad range of innovative pharmaceutical, biotechnology, medical device and diagnostics companies, primarily in the US and Europe. Our expertise spans the entire industry, and our track record includes successful placements in various business units, functions and therapeutic areas. Our thriving network, advanced search methodologies and rigorous qualification protocols enable us to identify candidates with the ability and sense of purpose to make a difference. Going beyond what’s on paper to find the right mindset, motivation and cultural fit is central to our approach. Our team shares a passion for the life sciences industry. Curiosity, creativity and persistence are in our DNA. Our firm mirrors the structure of a biotech firm, with leaders dedicated to recruiting in the discovery, clinical and commercial functions. Industry immersion gives us meaningful insight into the talent our clients need to achieve their next breakthrough – whether developing a lifesaving medicine, or entering a challenging new market. A Resource for Talent. A Partner in Success. Crossover Search works exclusively with clients in the life sciences sector, from early-stage biotech startups and mid-cap medical device and diagnostics firms to global pharmaceutical companies. We provide professional search and recruiting services aimed at ensuring that you have the talent you need, from the lab to the boardroom, to achieve your scientific and business goals. Talent strategy and HR consulting, as well as leadership and team assessment services make Crossover Search a comprehensive human capital resource, and a long-term partner. The People We Recruit:
We are dedicated to placing high-caliber professionals who are qualified, motivated, integrate with your team, and advance your organization’s endeavors. Focusing primarily on middle management through C-suite roles, we recruit for permanent positions at all levels, business units, functions and therapeutic areas across the life sciences sector: discovery & preclinical, clinical, and commercialization. The drive to positively impact the lives of patients and thrive in a competitive climate comes from the top. Our executive search services are geared to recruiting and developing senior managers and executives, as well as board members, who lead, inspire and innovate. Terms of Engagement:
Clients can choose to engage Crossover Search on a contingency or retained basis, or a combination of the two. As an agile, boutique firm, we can customize our services to your needs.

The Biotechnology Innovation Organization - BIO (BIO) has announced appointment Michelle McMurry-Heath, MD, PhD as the i...
05/19/2020

The Biotechnology Innovation Organization - BIO (BIO) has announced appointment Michelle McMurry-Heath, MD, PhD as the incoming President and CEO. BIO represents biotechnology companies, academic institutions, biotechnology centers, and service providers across the United States and more than 30 other nations. Upon discussing the appointment, BIO Chairman, Dr. Jeremy Levin, states that Dr. Michelle McMurryy-Heath is “most importantly devoted to innovation and patients” and she received a completely unanimous vote from the executive committee of BIO. To learn more about Dr. Michelle McMurry-Heath, take a look at the link below

Dr. Michelle McMurry-Heath named next President & CEO of the Biotechnology Innovation Organization (BIO).

05/18/2020

Congratulations to Deciphera Pharmaceuticals for receiving their first FDA approval. Their drug, Qinlock (ripretinib), was approved for adult patients with advanced gastrointestinal stromal tumor (GIST) who have received three prior therapies. Ripretinib is also in clinical studies for GIST 2nd line, systematic mastocytosis, and certain solid tumors.

Steve Hoerter, President and CEO of Deciphera stated, “The FDA approval of QINLOCK is an exciting milestone for people with GIST who have been waiting for a new treatment option designed specifically for their disease. I would like to thank the patients, their families and caregivers, and the healthcare professionals who made the QINLOCK clinical studies possible. With their contributions and the dedication of the team at Deciphera, we are delivering on our promise to provide important new medicines for the treatment of cancer.” Check out the full press release below –

The Investor Relations website contains information about Deciphera Pharmaceuticals, Inc.'s business for stockholders, potential investors, and financial analysts.

Great article explaining the coronavirus vaccine candidate landscape - currently, there are over 100 programs in develop...
04/16/2020

Great article explaining the coronavirus vaccine candidate landscape - currently, there are over 100 programs in development with 5 already in the clinic. This article touches on major industry collaborations, the types of vaccines in development, logistics of scaling up production, etc. Check out this amazing resource below.

Time for another look at the coronavirus vaccine front, since we have several recent news items. Word has come from GSK and Sanofi that they are going to collaborate on vaccine development, which brings together two of the more experienced large organizations in the field. It looks like Sanofi is br

Today, Alnylam Pharmaceuticals announced that they completed submission of an NDA for lumasiran in treating primary hype...
04/07/2020

Today, Alnylam Pharmaceuticals announced that they completed submission of an NDA for lumasiran in treating primary hyperoxaluria type 1 (PH1) – an ultra-rare genetic disease that can ultimately lead to kidney failure. This NDA submission marks a major milestone for the PH1 community as there are currently no approved therapeutics for the disease. Take a look at Alnylam’s press release below!

Alnylam Pharmaceuticals Press Release | Apr 07, 2020

Our client, Y-mabs Therapeutics, announced yesterday that they completed submission of a BLA for their lead drug candida...
04/02/2020

Our client, Y-mabs Therapeutics, announced yesterday that they completed submission of a BLA for their lead drug candidate, naxitamab for treatment of pediatric patients with relapsed/refractory high-risk neuroblastoma. This submission is based on safety and efficacy data that Y-mAbs expects to present later in 2020.

The CEO of Y-mAbs stated, “With this submission, we look forward to working with the Agency to bring naxitamab to appropriate patients. We are excited to complete this submission and believe naxitamab can address a significant unmet medical need for children with relapsed/refractory high-risk neuroblastoma.”

Check out the full press release below!

NEW YORK , April 01, 2020 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, toda...

Exciting news for our friends at bluebird bio! Today, bluebird announced that they submitted a BLA for their lead CAR-T ...
03/31/2020

Exciting news for our friends at bluebird bio! Today, bluebird announced that they submitted a BLA for their lead CAR-T immunotherapy, idecabtagene vicleucel, in treating adult patients with multiple myeloma.

Idecabtagene vicleucel, also referred to as bb2121, is the first CAR-T therapy filed for multiple myeloma. Check out bluebird bio's press release below:


The Investor Relations website contains information about bluebird bio, Inc.'s business for stockholders, potential investors, and financial analysts.

Check out this Global Coronavirus COVID-19 Clinical Trial Tracker, prepared by Cytel and in partnership with Bill & Meli...
03/31/2020

Check out this Global Coronavirus COVID-19 Clinical Trial Tracker, prepared by Cytel and in partnership with Bill & Melinda Gates Foundation. It gives a broad and accurate overview of COVID-19 Clinical Trials taking place across the globe. Thank you to all of the exceptional healthcare workers for their tireless efforts!

If you have a favorite resource that you have been using to track progress, leave a link in our comments! We have been amazed with the creative ways people are organizing and sharing data.

http://ec2-3-22-22-146.us-east-2.compute.amazonaws.com:3838/ubuntu/COVID-RShinyApp/

03/20/2020

Although the last 2 weeks have been challenging, we remain inspired by our colleagues, friends and partners across the life sciences industry. The resiliency and passion of the people within this industry is on full display & there is optimism that they will develop new diagnostics, vaccines and treatments that will hopefully alter the course of this epidemic.

03/12/2020

At Crossover Search, we have given our employees the choice to work from home due to coronavirus (COVID-19) and it has sparked some fascinating conversations.

Some of the concerns our team had:

Will working from home impact our company culture? How to self-motivate and stay focused? How to handle technical difficulties and what if you just aren’t that tech savvy? Will we miss out on important information? Will this limit creativity? What if this working style doesn’t work for everyone?

Some positives:

Less distractions! Much easier to stay focused and prioritize. Builds knowledge of the technologies available to stay connected and collaborate – something profoundly important in the recruiting industry. Helps us to understand and define the learning/working style of each of our employees, offering insight we may never have taken the time to understand.

We want to know your thoughts! How is your company navigating coronavirus?

Congratulations to our friends and colleagues at AVROBIO! The FDA has granted orphan drug designation for AVR-RD-04, AVR...
03/11/2020

Congratulations to our friends and colleagues at AVROBIO! The FDA has granted orphan drug designation for AVR-RD-04, AVROBIO’s investigational gene therapy program for .

AVR-RD-04 is the third AVROBIO investigational gene therapy to receive orphan status CAMBRIDGE, Mass. --(BUSINESS WIRE)-- AVROBIO, Inc . (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the U.S.

Address

New York, NY

Alerts

Be the first to know and let us send you an email when Crossover Search posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Crossover Search:

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram